Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
NCT ID: NCT03486665
Last Updated: 2018-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2018-04-24
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T Cell Vaccination in Patients With Progressive Multiple Sclerosis
NCT01448252
Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients
NCT01918501
Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients
NCT02142764
Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
NCT03138525
T-Cell Vaccination in Multiple Sclerosis (MS)
NCT00220428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnosed with Multiple Sclerosis
Patients previously diagnosed with Multiple Sclerosis
Blood Sampling
Blood samples will be taken from all patients and healthy volunteers.
Newly Diagnosed with Multiple Sclerosis
Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
Blood Sampling
Blood samples will be taken from all patients and healthy volunteers.
CSF Sampling
CSF sample will be taken from hospitalized newly diagnosed patients only.
Healthy Volunteers
Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
Blood Sampling
Blood samples will be taken from all patients and healthy volunteers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Sampling
Blood samples will be taken from all patients and healthy volunteers.
CSF Sampling
CSF sample will be taken from hospitalized newly diagnosed patients only.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide written informed consent.
Exclusion Criteria
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bioimmunate
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Center
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ariel Ginzberg, PHD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIT-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.